Grants Immunobiology LGM

Grant Updates: March & April 2018

Nearly $3.9 million in grants awarded to faculty in Immunobiology and Laboratory & Genomic Medicine

Carey-Ann Burnham, Ph.D., Associate Professor of Pathology and Immunology, of Pediatrics, and of Molecular Microbiology, and Medical Director, Clinical Microbiology Laboratory, received a five-month $10,568 grant from the National Institutes of Health, entitled “A Cloud-Based WGS Platform for Routine Surveillance of Plasmid-Borne Carbapenem Resistance”.

Brian Edelson, M.D., Ph.D., Assistant Professor of Pathology and Immunology, received a one-year $59,500 grant from the Washington University Institute of Clinical and Translational Sciences/Foundation for Barnes Jewish-Hospital, entitled Dissecting Multiple Sclerosis Pathogenesis at Single-Cell Resolution”.

Gwendolyn Randolph, Ph.D., Emil R. Unanue Professor of Pathology and Immunology and of Medicine, and Head, Division of Immunobiology, received a one-year $300,000 grant from The Kenneth Rainin Foundation, entitled “Toward Identifying the Unique Pathology that Explains Ulcerative Colitis Distribution”.

Jesse Williams, Ph.D., Postdoc Research Associate in Immunobiology in the Gwendalyn Randolph Lab, received a two-year $249,038 grant from the National Institutes of Health, entitled “Atherosclerotic Lesion Initiation by Resident Aortic Macrophage Proliferation and Lipid Uptake”.

GRANTS PREVIOUSLY RECEIVED BUT NOT REPORTED

Ali Ellebedy, Ph.D., Assistant Professor, Pathology and Immunology, received a one-year $321,624 grant from the National Institutes of Health, entitled “Induction and Long Term Maintenance of Broadly Neutralizing B Cell Responses to Influenza in Humans”.

Thaddeus Stappenbeck, M.D., Ph.D., Conan Professor of Pathology and Immunology, Professor of Developmental Biology, and Co-Chief, Division of Laboratory and Genomic Medicine, received a three-year $3,000,000 grant from the The Crohn’s and Colitis Foundation of America, entitled “Development of Microbial Targets and Analytic Tools for Therapies Directed to Mucosal Damage in Ibd”.